Rajeev Saggar Sells 2,445 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,445 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the sale, the insider now owns 267,943 shares in the company, valued at approximately $3,483,259. This trade represents a 0.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Rajeev Saggar also recently made the following trade(s):

• On Tuesday, January 14th, Rajeev Saggar sold 6,249 shares of Liquidia stock. The stock was sold at an average price of $11.78, for a total transaction of $73,613.22.

Liquidia Trading Down 0.3 %

LQDA opened at $14.36 on Friday. The stock has a 50-day moving average of $11.65 and a 200-day moving average of $11.10. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.99.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Liquidia in a research report on Thursday, January 9th. Wells Fargo & Company assumed coverage on Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. Scotiabank started coverage on shares of Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Finally, Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Liquidia has an average rating of “Buy” and a consensus price target of $25.38.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of the company. Whitcomb & Hess Inc. grew its stake in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after buying an additional 1,074 shares during the last quarter. Catalina Capital Group LLC grew its position in shares of Liquidia by 6.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock valued at $215,000 after purchasing an additional 1,125 shares during the last quarter. DMC Group LLC increased its stake in shares of Liquidia by 17.4% in the fourth quarter. DMC Group LLC now owns 16,302 shares of the company’s stock worth $192,000 after purchasing an additional 2,419 shares during the period. Profund Advisors LLC lifted its position in shares of Liquidia by 31.6% during the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock worth $173,000 after purchasing an additional 3,466 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Liquidia by 25.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,706 shares of the company’s stock valued at $272,000 after buying an additional 4,572 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).